JP7280638B2 - ドライアイ症候群の治療におけるリポソーム点眼剤溶液およびその使用 - Google Patents
ドライアイ症候群の治療におけるリポソーム点眼剤溶液およびその使用 Download PDFInfo
- Publication number
- JP7280638B2 JP7280638B2 JP2021514622A JP2021514622A JP7280638B2 JP 7280638 B2 JP7280638 B2 JP 7280638B2 JP 2021514622 A JP2021514622 A JP 2021514622A JP 2021514622 A JP2021514622 A JP 2021514622A JP 7280638 B2 JP7280638 B2 JP 7280638B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- solution
- eye drop
- aqueous
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims description 26
- 206010013774 Dry eye Diseases 0.000 title claims description 25
- 239000002997 ophthalmic solution Substances 0.000 title claims description 4
- 229940054534 ophthalmic solution Drugs 0.000 title claims 3
- 239000002502 liposome Substances 0.000 claims description 57
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 48
- 239000003889 eye drop Substances 0.000 claims description 33
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 31
- 229940108325 retinyl palmitate Drugs 0.000 claims description 31
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 31
- 239000011769 retinyl palmitate Substances 0.000 claims description 31
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 claims description 29
- 238000001914 filtration Methods 0.000 claims description 29
- 239000000944 linseed oil Substances 0.000 claims description 27
- 235000021388 linseed oil Nutrition 0.000 claims description 27
- 239000011715 vitamin B12 Substances 0.000 claims description 20
- 229930003779 Vitamin B12 Natural products 0.000 claims description 19
- 235000019163 vitamin B12 Nutrition 0.000 claims description 19
- 150000003904 phospholipids Chemical class 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 229940012356 eye drops Drugs 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241001236212 Pinus pinaster Species 0.000 claims description 4
- 235000005105 Pinus pinaster Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 230000002411 adverse Effects 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940106587 pine bark extract Drugs 0.000 claims 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229920002770 condensed tannin Polymers 0.000 description 49
- 235000018192 pine bark supplement Nutrition 0.000 description 49
- 229940106796 pycnogenol Drugs 0.000 description 49
- 238000009472 formulation Methods 0.000 description 40
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 27
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 17
- 230000003078 antioxidant effect Effects 0.000 description 16
- 229930003427 Vitamin E Natural products 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 13
- 229940046009 vitamin E Drugs 0.000 description 13
- 235000019165 vitamin E Nutrition 0.000 description 13
- 239000011709 vitamin E Substances 0.000 description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Natural products OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 235000019155 vitamin A Nutrition 0.000 description 7
- 239000011719 vitamin A Substances 0.000 description 7
- 229940045997 vitamin a Drugs 0.000 description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 3
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010015958 Eye pain Diseases 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 3
- 235000012734 epicatechin Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004489 tear production Effects 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000006240 Linum usitatissimum Species 0.000 description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940093797 bioflavonoids Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 235000004426 flaxseed Nutrition 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 150000004291 polyenes Polymers 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100609 all-trans-retinol Drugs 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- ZMOMAWYIEDMDCZ-UHFFFAOYSA-N boric acid decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.B(O)(O)O.B(O)(O)O.B(O)(O)O.B(O)(O)O.B(O)(O)O ZMOMAWYIEDMDCZ-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid group Chemical class C(C=CC1=CC=CC=C1)(=O)O WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000027483 retinoid hormone receptors Human genes 0.000 description 1
- 108091008679 retinoid hormone receptors Proteins 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Description
-灼熱感眼のかゆみ疼痛 重眼
-眼の疲れ
-眼の痛み 乾燥感
-眼の赤み
-羞明(光感受性)
-眼のかすみ
ドライアイは、十分な涙がないことが原因で起こる。涙は、水、脂肪油および粘液の複合混合物である。この混合物は、眼の表面を滑らかで透明にするのに役立ち、感染から眼を保護するのに役立つ。
涙液産生の減少
加齢
-糖尿病、関節リウマチ、狼瘡、強皮症、シェーグレン症候群、甲状腺疾患およびビタミンA欠乏症などの特定の医学的状態;
-抗ヒスタミン薬、充血緩和薬、ホルモン補充療法剤、抗うつ剤、高血圧、座瘡、受胎調節およびパーキンソン病に対する薬剤などの特定の薬;
-レーザー眼科手術、ただし、この手順に関連するドライアイの症状は通常一時的なものである;
-炎症または放射線による涙腺損傷;
1.油性(脂質)成分
2.水様(水性)成分
3.粘液様(ムチン)成分
上記のドライアイ症候群の悪影響を解決するか、少なくとも部分的に軽減するために、出願人は以下の成分が存在する必要がある製剤を研究し、開発した;
抗炎症作用を有する;
抗酸化作用を有する;
眼の表面の油層を回復させる;
水分を維持する;
滅菌が可能である。
-製品の安定性/沈降
-完全には溶解しないため、UVA/UVB光線に対するピクノジェノールの遮蔽効果が低い。
1)製剤が不安定である可能性(ピクノジェノール微細粒子の沈降によって紫外線に対して効果的な遮蔽効果をもたらさない)
2)製剤の濾過が困難であること、は未解決のままである。
抗炎症作用があり、
抗酸化作用があり、
神経因性眼痛に対抗する眼の表面の油層を回復し、
水分を維持する。
-ビタミンAパルミテート0.010%、ビタミンE TPGS 0.025%(リポソームの内側);
-ビタミンAパルミテート0.010%、ビタミンE TPGS 0.025%(リポソーム中)+ピクノジェノール0.017%(水相);
-ビタミンAパルミテート0.010%、ビタミンE TPGS 0.025%(リポソームの内側)+ビタミンB12 0.0035%(水相);および
-ビタミンAパルミテート0.010%+ビタミンE TPGS 0.025%(リポソームの内側)+ピクノジェノール0.017%+ビタミンB12 0.0035%(水相)。
・200nm 60mワット
・250nm 90mワット
・300nm 125mワット
・350nm 137mワット
・400nm 118mワット
-ビタミンE TPGSをそのまま含有するリポソームによって保護される。
-ビタミンAパルミテートは、
-リポソーム構造の内側のビタミンE TPGS、および
-リポソームの外側、水相の内側のピクノジェノール、ビタミンB12によって保護される。
-このリポソーム点眼剤溶液は、蒸気滅菌(121℃、1気圧で15分間)ではリポソームの全ての成分が破壊されるため、0.2マイクロメートルでの濾過により滅菌しなければならない。
1)全ての親油性成分、非水素化リン脂質、亜麻仁油、ビタミンAパルミテート+ビタミンE TPGSビタミンを溶媒(通常はエタノール)により可溶化する;
2)その溶媒を真空下で除去して、乾燥粉末を得る;
3)その粉末をホウ酸緩衝液に分散させ、機械式ミキサーで混合し、プロリポソームと定義され得る大きなリポソームの溶液を得る;
4)次に、かかる大きなリポソームの溶液を、600/1000バールの範囲の高圧で押し出す;
5)この高圧での押し出し手順を数回(4/7)繰り返して、200nm未満のサイズのリポソームを得る。
6)蒸留水にピクノジェノール、トリス、ビタミンB12、ヒアルロン酸およびホウ酸緩衝液を可溶化する;
7)透明で赤色の溶液が得られる。
8)第1工程で調製したリポソーム溶液(100リットル)を、第2工程で調製した着色した水溶液(100リットル)に添加し、0.2マイクロメートルのフィルターで濾過することにより滅菌し、以下の処方を有する最終標準点眼剤溶液を得た:
1) Anti-inflammatory, analgesic and antipyretic activities of Linum usitatissimum L. (flaxseed/linseed) fixed oil.
Kaithwas G1, Mukherjee A, Chaurasia AK, Majumdar DK.
2) Ocul Surf. 2009 Oct;7(4):176-85.
Antioxidant defenses in the ocular surface.
Chen Y1, Mehta G, Vasiliou V.
3) Are Phospholipids the Critical Ingredient?.
Donald Korb, O.D., and Ralph Stone, Ph.D.
4)The effects of pycnogenol on antioxidant enzymes in a mouse model of ozone exposure
Min-Sung Lee,1 Kuk-Young Moon,1 Da-Jeong Bae,1 Moo-Kyun Park,2 and An-Soo Jang1
5) Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1173-1177. doi: 10.1007/s00417-017-3632-y. Epub 2017 Mar 15.
Ozen S1, Ozer MA2, Akdemir MO3.
6)Arch Biochem Biophys. 1996 Feb 1;326(1):57-63.
Synergistic interactions between vitamin A and vitamin E against lipid peroxidation in phosphatidylcholine liposomes.
Tesoriere L1, Bongiorno A, Pintaudi AM, D’Anna R, D’Arpa D, Livrea MA.
7)Vitamin E TPGS as a Molecular Biomaterial for Drug Delivery
Biomaterials 33(19):4889-9062012 with 203 Reads DOI: 10.1016/j.biomaterials.2012.03.046 Source: PubMed
8) Using Tocophersolan for Drug Delivery: A natural vitamin E derivative is an innovative excipient
Jan 02, 2015By Yves RobinPharmaceutical Technology Volume 39, Issue 1
9)Pucker AD, Ng SM, Nichols JJ (2016). “Over the counter (OTC) artificial tear drops for dry eye syndrome”. Cochrane Database Syst Rev.2: CD009729.
10) UltraPureTM Buffer-Saturated Phenol Catalog number: 15513047
11) Ketorolac Trometamin salt anti inflammatory drug
Molar mass: 255,27 g/mol
12) VIII. Evfolyam 3. szam - 2013. szeptember
Kolonics Gィ「bor THE EXAMINATION OF UV ABSORPTION OF POLYPHENOLS (NATURAL SUBSTANCE)
Claims (9)
- 亜麻仁油、ビタミンAパルミテートおよびビタミンE TPGSを含有する非水素化リン脂質で構築されたリポソーム、ビタミンB12およびフランス海岸松樹皮抽出物を含有する、ドライアイ症候群の治療に使用する水性点眼剤溶液。
- 前記水性点眼剤溶液が更に、フランス海岸松樹皮抽出物の塩形成剤として作用する2-アミノ-2(ヒドロキシメチル)プロパン-1,3-ジオール、および緩衝液pH調節剤を含有する、請求項1に記載の水性点眼剤溶液。
- 前記点眼剤溶液が0.2μm(0.2マイクロメートル)での濾過によって滅菌されることを特徴とする、請求項1~2のいずれか一項に記載の水性点眼剤溶液。
- 前記点眼剤溶液が、UVA/UVB光線に対する遮蔽効果を発揮することを特徴とする、請求項1~3のいずれか一項に記載の水性点眼剤溶液。
- ドライアイ症候群の治療に使用するための点眼剤溶液の調製プロセスであって、親油性物質を担持するリポソームを調製する第1工程:
a)全ての親油性成分、非水素化リン脂質、亜麻仁油、ビタミンAパルミテートおよびビタミンE TPGSを溶媒により可溶化し、
b)前記溶媒を真空下で除去して、乾燥粉末が得られ;
c)前記粉末をホウ酸緩衝液に分散させ、機械式ミキサーで混合して、プロリポソームと定義され得る大きなリポソームの溶液が得られ;
d)次に、かかる大きなリポソームの溶液を、600/1000バールの高圧で押し出し;
e)高圧での押し出し手順を数回(4~7回)繰り返して、200nm未満のサイズのリポソームを得る、工程;
親水性物質を含有する水溶液を調製する第2工程:
f)蒸留水にフランス海岸松樹皮抽出物、トリス、ビタミンB12、ヒアルロン酸およびホウ酸緩衝液を可溶化し、透明で赤色の溶液を得る工程であって、第1工程における親油性物質の濃度および第2工程における親水性物質の濃度は、所望の濃度の溶液を得るために、容積1:1で互いに添加することを可能にするようなものであり;
最終滅菌点眼剤を調製する第3工程:
g)第1工程で調製したリポソーム溶液の量「X」を、第2工程で調製した同量の「X」の透明の水溶液の量に添加することで、最終標準点眼剤溶液「2X」が得られ、
h)最終的な標準点眼溶液が、0.2μm(0.2マイクロメートル)の濾過で滅菌される工程、を含む調製プロセス。 - UVA/UVB光線に対する遮蔽として使用される、請求項4および5のいずれか一項に記載の水性点眼剤溶液。
- ドライアイ症候群の悪影響を軽減するために使用される、請求項1~6のいずれか一項に記載の水性点眼剤溶液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18425109.8 | 2018-12-28 | ||
EP18425109.8A EP3673896B9 (en) | 2018-12-28 | 2018-12-28 | Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome |
PCT/EP2019/079029 WO2020135940A1 (en) | 2018-12-28 | 2019-10-24 | Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022514809A JP2022514809A (ja) | 2022-02-16 |
JPWO2020135940A5 JPWO2020135940A5 (ja) | 2022-06-08 |
JP7280638B2 true JP7280638B2 (ja) | 2023-05-24 |
Family
ID=65657191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021514622A Active JP7280638B2 (ja) | 2018-12-28 | 2019-10-24 | ドライアイ症候群の治療におけるリポソーム点眼剤溶液およびその使用 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220304970A1 (ja) |
EP (1) | EP3673896B9 (ja) |
JP (1) | JP7280638B2 (ja) |
KR (1) | KR102493604B1 (ja) |
CN (1) | CN112804990B (ja) |
AU (1) | AU2019412448B2 (ja) |
CA (1) | CA3124727C (ja) |
DK (1) | DK3673896T3 (ja) |
ES (1) | ES2910121T3 (ja) |
HR (1) | HRP20220180T1 (ja) |
IL (1) | IL284454B1 (ja) |
PH (1) | PH12021551094A1 (ja) |
PL (1) | PL3673896T3 (ja) |
PT (1) | PT3673896T (ja) |
SG (1) | SG11202105666WA (ja) |
WO (1) | WO2020135940A1 (ja) |
ZA (1) | ZA202104891B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111671722A (zh) * | 2020-07-30 | 2020-09-18 | 成都大学 | 一种滴眼液及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850054A (zh) | 2006-06-05 | 2006-10-25 | 珠海丽波医药科技有限公司 | 维生素a脂质体人工泪滴眼液 |
JP2012505244A (ja) | 2008-10-09 | 2012-03-01 | ラムズコア, インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
CN102100665B (zh) | 2011-01-14 | 2012-05-30 | 华南理工大学 | 一种含维生素e衍生物的滴眼液及其制备方法 |
US20130108674A1 (en) | 2010-06-11 | 2013-05-02 | Medivis S.R.L. | Ophthalmic compositions for the administration of liposoluble active ingredients |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1170364A (zh) * | 1994-12-19 | 1998-01-14 | 大正制药株式会社 | 脂质体滴眼液 |
US20060127505A1 (en) * | 2002-01-16 | 2006-06-15 | David Haines | Anti-inflammatory formulations |
US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
ITRM20030153A1 (it) * | 2003-04-03 | 2004-10-04 | Exall S R L | Formulazione idrosolubile contenente ubichinone per uso oftalmico. |
EP1502594A1 (en) * | 2003-07-31 | 2005-02-02 | Pynogin GmbH | A health care composition for decreasing the risk of thrombosis including a mixture of proanthocyanidins and sesquiterpenes |
CA2640986C (en) * | 2007-08-16 | 2014-10-21 | Reza Dana | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
KR20090126785A (ko) * | 2008-06-05 | 2009-12-09 | 홉킨스바이오연구센터(주) | 피크노제놀, 레스베라트롤 및 항산화 비타민을 함유하는항산화 복합 조성물 |
WO2017115316A1 (en) * | 2015-12-29 | 2017-07-06 | Noivita S.R.L.S. | Lipophilic formulations |
EP3412276A3 (de) * | 2017-06-09 | 2019-07-17 | Omnivision GmbH | Zusammensetzung zur behandlung des trockenen auges |
KR101882736B1 (ko) * | 2017-07-10 | 2018-07-27 | 김삼 | 멜라토닌, 비타민 c 및 피크노제놀을 유효 성분으로 함유한 피부보호용 조성물 |
-
2018
- 2018-12-28 DK DK18425109.8T patent/DK3673896T3/da active
- 2018-12-28 PL PL18425109T patent/PL3673896T3/pl unknown
- 2018-12-28 ES ES18425109T patent/ES2910121T3/es active Active
- 2018-12-28 PT PT184251098T patent/PT3673896T/pt unknown
- 2018-12-28 HR HRP20220180TT patent/HRP20220180T1/hr unknown
- 2018-12-28 EP EP18425109.8A patent/EP3673896B9/en active Active
-
2019
- 2019-10-24 KR KR1020217023928A patent/KR102493604B1/ko active IP Right Grant
- 2019-10-24 SG SG11202105666WA patent/SG11202105666WA/en unknown
- 2019-10-24 IL IL284454A patent/IL284454B1/en unknown
- 2019-10-24 US US17/418,908 patent/US20220304970A1/en not_active Abandoned
- 2019-10-24 CN CN201980065758.4A patent/CN112804990B/zh active Active
- 2019-10-24 CA CA3124727A patent/CA3124727C/en active Active
- 2019-10-24 AU AU2019412448A patent/AU2019412448B2/en active Active
- 2019-10-24 JP JP2021514622A patent/JP7280638B2/ja active Active
- 2019-10-24 WO PCT/EP2019/079029 patent/WO2020135940A1/en active Application Filing
-
2021
- 2021-05-11 PH PH12021551094A patent/PH12021551094A1/en unknown
- 2021-07-12 ZA ZA2021/04891A patent/ZA202104891B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850054A (zh) | 2006-06-05 | 2006-10-25 | 珠海丽波医药科技有限公司 | 维生素a脂质体人工泪滴眼液 |
JP2012505244A (ja) | 2008-10-09 | 2012-03-01 | ラムズコア, インコーポレイテッド | ドライアイ症候群の処置のための組成物および方法 |
US20130108674A1 (en) | 2010-06-11 | 2013-05-02 | Medivis S.R.L. | Ophthalmic compositions for the administration of liposoluble active ingredients |
CN102100665B (zh) | 2011-01-14 | 2012-05-30 | 华南理工大学 | 一种含维生素e衍生物的滴眼液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
HRP20220180T1 (hr) | 2022-04-29 |
ES2910121T3 (es) | 2022-05-11 |
CN112804990A (zh) | 2021-05-14 |
AU2019412448B2 (en) | 2023-04-20 |
CA3124727A1 (en) | 2020-07-02 |
EP3673896B9 (en) | 2022-05-18 |
PL3673896T3 (pl) | 2022-06-27 |
KR102493604B1 (ko) | 2023-01-31 |
IL284454B1 (en) | 2024-04-01 |
SG11202105666WA (en) | 2021-07-29 |
PT3673896T (pt) | 2022-02-03 |
US20220304970A1 (en) | 2022-09-29 |
PH12021551094A1 (en) | 2021-11-22 |
AU2019412448A1 (en) | 2021-08-12 |
CA3124727C (en) | 2023-10-31 |
DK3673896T3 (da) | 2022-02-07 |
EP3673896A1 (en) | 2020-07-01 |
KR20210110653A (ko) | 2021-09-08 |
CN112804990B (zh) | 2024-05-24 |
EP3673896B1 (en) | 2022-01-12 |
WO2020135940A1 (en) | 2020-07-02 |
IL284454A (en) | 2021-08-31 |
JP2022514809A (ja) | 2022-02-16 |
ZA202104891B (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2009302167B9 (en) | Composition and method for treating dry eye syndrome | |
Gunjan et al. | Topical delivery of Curcuma longa extract loaded nanosized ethosomes to combat facial wrinkles | |
HUE030841T2 (en) | Preparations containing quaternary ammonium compounds | |
Soleymani et al. | Implications of grape extract and its nanoformulated bioactive agent resveratrol against skin disorders | |
JP7280638B2 (ja) | ドライアイ症候群の治療におけるリポソーム点眼剤溶液およびその使用 | |
JP2017533970A (ja) | 加齢性疾患に対する脂溶性化合物の改善されたバイオアベイラビリティーに対する安定な固体脂質粒子組成物 | |
JP6907243B2 (ja) | 医薬目的のレスベラトロール可溶化製品 | |
CA3018636C (en) | Storage stable, ophthalmic composition | |
Sabeti et al. | Characterization of diclofenac liposomes formulated with palm oil fractions | |
RU2781131C1 (ru) | Раствор липосомальных глазных капель и варианты его применения для лечения синдрома сухого глаза | |
PL223972B1 (pl) | Olejek szałwiowy do zastosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek oraz kompozycja farmaceutyczna zawierająca olejek szałwiowy do zastosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek | |
RU2602169C2 (ru) | Водный ионный раствор, содержащий морскую воду и по меньшей мере одно соединение, изначально не смешивающееся с морской водой | |
ES2938493T3 (es) | Preparación y uso de nanoformulación de cannabis | |
RU2817530C1 (ru) | Получение и применение наносостава конопли | |
JP2024514444A (ja) | ルテイン含有水溶性局所眼科用製剤及びその製造方法 | |
Bonilla-Vidal et al. | Novel nanostructured lipid carriers loading Apigenin for anterior segment ocular pathologies | |
Favero et al. | Evidence of Polyphenols Efficacy against Dry Eye Disease. Antioxidants 2021, 10, 190 | |
Minnelli | Natural and functionalized molecules with antioxidant and scavenging activity as components of innovative lipid-based artificial tears | |
Sarhan et al. | Penetration enhancer containing vesicles for dermal and transdermal drug delivery. A review. | |
WO2023084038A1 (de) | Selbstemulgierende öl-in wasser-mikro- oder nanoemulsion sowie emulgierende zusammensetzung | |
IT202100013787A1 (it) | Composizione per l’uso nel trattamento di affezioni oculari, quali sindrome dell’occhio secco, specialmente post-chirurgico oftalmico / a composition for use in the treatment of ocular affections, such as dry eye disease, especially after eye surgery | |
US20090274750A1 (en) | Therapeutic Treatment of Dermatologic Skin Disorders | |
BRPI1001009A2 (pt) | composições micro e nanoestruturadas para aplicação ocular no tratamento de ceratocone | |
PL225087B1 (pl) | Olejek lawendowy do zastosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek oraz kompozycja farmaceutyczna zawierająca olejek lawendowy do zastosowanie w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek | |
PL225086B1 (pl) | Olejek eukaliptusowy do zastosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek oraz kompozycja farmaceutyczna zawierająca olejek eukaliptusowy do zastosowania w leczeniu i profilaktyce stanów zapalnych wywołanych przez nużeńce, zwłaszcza zapalenia brzegów powiek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220531 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220531 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20220531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230215 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230502 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7280638 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |